2cureX AB’s Executive Management is pleased to invite shareholders and investors to a live webcast and business update on 20 May at 7pm CET.
Idag, 20:05
Live access to the webcast: https://www.2curex.se/2curex-webinar-260520
During the webcast, CEO Nat Hutley will provide an update on the strategic evolution of 2cureX AB and the company’s broader positioning within the emerging Functional Precision Medicine sector.
The presentation will focus on the development of a broader Functional Precision Medicine ecosystem strategy, including operational infrastructure, commercial positioning, decentralised laboratory partnerships, patient access pathways, and the continued expansion of collaborative relationships across the sector.
The webcast will also revisit the strategic framework established between 2cureX AB, PreComb and 2cureX A/S, and discuss how these relationships support the company’s ambition to establish a broader and more integrated presence within Functional Precision Medicine over time.
The presentation will be followed by a live Q&A session. Shareholders are also welcome to submit questions in advance by emailing ir@2curex.com.
A replay of the webcast will be made available following the event at www.2curex.se.
We look forward to your participation.
For more information about 2cureX:
Nathaniel Hutley, Interim CEO
E-mail: NH@2curex.com
Telephone: +44 (776) 514 1346
About 2cureX
2cureX is redefining cancer treatment selection through functional precision oncology. Its proprietary IndiTreat® test family creates thousands of 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are most effective for that specific tumor. The result: real data to drive real decisions.
The first three IndiTreat® tests target patients with metastatic colorectal cancer:
• IndiTreat® Start (first-line therapy)
• IndiTreat® Extend & Explore (third-line options)
New IndiTreat® versions are in development for earlier-stage colorectal cancer and other GI cancers.
Despite global cancer IVD spending exceeding $17.5 billion annually, fewer than 1 in 3 treatments are guided by a predictive test. IndiTreat® aims to close that gap—bringing clarity to treatment selection and precision to every patient.
2cureX AB is listed on Nasdaq First North Growth Market under the ticker 2CUREX, with operational delivery in partnership with 2cureX A/S in Denmark. This cross-border structure powers the company’s new commercial strategy, Operation Twin Code—now live.
Attachments
Ämnen i artikeln
2cureX AB’s Executive Management is pleased to invite shareholders and investors to a live webcast and business update on 20 May at 7pm CET.
Idag, 20:05
Live access to the webcast: https://www.2curex.se/2curex-webinar-260520
During the webcast, CEO Nat Hutley will provide an update on the strategic evolution of 2cureX AB and the company’s broader positioning within the emerging Functional Precision Medicine sector.
The presentation will focus on the development of a broader Functional Precision Medicine ecosystem strategy, including operational infrastructure, commercial positioning, decentralised laboratory partnerships, patient access pathways, and the continued expansion of collaborative relationships across the sector.
The webcast will also revisit the strategic framework established between 2cureX AB, PreComb and 2cureX A/S, and discuss how these relationships support the company’s ambition to establish a broader and more integrated presence within Functional Precision Medicine over time.
The presentation will be followed by a live Q&A session. Shareholders are also welcome to submit questions in advance by emailing ir@2curex.com.
A replay of the webcast will be made available following the event at www.2curex.se.
We look forward to your participation.
For more information about 2cureX:
Nathaniel Hutley, Interim CEO
E-mail: NH@2curex.com
Telephone: +44 (776) 514 1346
About 2cureX
2cureX is redefining cancer treatment selection through functional precision oncology. Its proprietary IndiTreat® test family creates thousands of 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are most effective for that specific tumor. The result: real data to drive real decisions.
The first three IndiTreat® tests target patients with metastatic colorectal cancer:
• IndiTreat® Start (first-line therapy)
• IndiTreat® Extend & Explore (third-line options)
New IndiTreat® versions are in development for earlier-stage colorectal cancer and other GI cancers.
Despite global cancer IVD spending exceeding $17.5 billion annually, fewer than 1 in 3 treatments are guided by a predictive test. IndiTreat® aims to close that gap—bringing clarity to treatment selection and precision to every patient.
2cureX AB is listed on Nasdaq First North Growth Market under the ticker 2CUREX, with operational delivery in partnership with 2cureX A/S in Denmark. This cross-border structure powers the company’s new commercial strategy, Operation Twin Code—now live.
Attachments
Ämnen i artikeln
Nibe
Evolution
Nibe
Evolution
Marknadsöversikt
1 DAG %
Senast
1 mån
